Skip to Content

Generic Calcijex Availability

Calcijex is a brand name of calcitriol, approved by the FDA in the following formulation(s):

CALCIJEX (calcitriol - injectable;injection)

  • Manufacturer: ABBVIE
    Approval date: September 25, 1986
    Strength(s): 0.001MG/ML, 0.002MG/ML

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Calcijex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Low oxygen content compositions of 1.alpha., 25-dihydroxycholecalciferol
    Patent 6,051,567
    Issued: April 18, 2000
    Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan
    Assignee(s): Abbott Laboratories
    The invention relates to stable aqueous formulations comprising 1.alpha., 25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
    Patent expiration dates:
    • August 2, 2019
    • February 2, 2020
      ✓ 
      Pediatric exclusivity
  • Low oxygen content compositions of 1.alpha., 25-dihydroxycholeclciferol
    Patent 6,265,392
    Issued: July 24, 2001
    Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan
    Assignee(s): Abbott Laboratories
    The invention relates to stable aqueous formulations comprising 1.alpha.,25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
    Patent expiration dates:
    • August 2, 2019
    • February 2, 2020
      ✓ 
      Pediatric exclusivity
  • Low oxygen content compostions of 1.alpha., 25-dihydroxycholecalciferol
    Patent 6,274,169
    Issued: August 14, 2001
    Inventor(s): Abrahamson; Kent & Anderson; Amy N. & Grady; Haiyan & Hartmann; Kurt J. & Farmer; Randall M. & Oberdier; John P.
    Assignee(s): Abbott Laboratories
    The invention relates to stable compositions comprising 1.alpha., 25-dihydroxycholecalciferol, a unit dose system comprising the same in a sealed vessel, and a process for preparing them.
    Patent expiration dates:
    • August 2, 2019
    • February 2, 2020
      ✓ 
      Pediatric exclusivity

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide